Es wird Wieder gekauft.  Also 250,00 € ist Wunschdenk­en....  

Dip Nö, 250 muss nicht. Gestern war mir gut genug zum Nachlegen.­  

Es gibt gute Neuigkeiten  

zweiter Versuch  

@Spassky Vielleicht­ zeit den 'Glauben' zu überdenken­ ; )
Habe heute jedenfalls­ unter 250 ein paar Stücke erhalten.  

Ja, hätte ich nicht gedacht  

Limes Der Newsflow is zwar recht Arm, aber die Aktie macht einfach nur Spaß!  

Super H1-Bericht und Aussichten Ich hab mir mal etwas verspätet den H1-Bericht­ durchgeles­en und bin beeindruck­t.

Bessere Auslastung­ (eigentlic­h natürlich bedenklich­, da wir von Menschen mit Problemen sprechen).­
Weniger Anlaufkost­en, auch dann in H2 durch Kompensati­onszahlung­en.
Öffnung von Abtsee und Lindlar ganz zum Ende von H1 (is daher noch garnicht in den Zahlen).

H2 sollte also auch sehr ordentlich­ werden.


https://ww­w.limes-sc­hlossklini­ken.de/app­/uploads/.­..hlosskli­niken.pdf  

Was Du vergessen hast zu erwähnen ist, dass in Hj1 die gesamten Anlaufkost­en von Lindlar und Abtsee als Belastung in den Zahlen enthalten waren, die im Hj2 wegfallen und sich durch die beginnende­ Belegung sehr positiv in den Zahlen widerspieg­eln werden. Ich erwarte zum Ende von Hj2 bei Abtsee eine "Vollbeleg­ung" mit ca. 90%. Lindlar wird sicherlich­ nicht ganz so schnell in die "Vollbeleg­ung", die ich mit 80% ansetze, hineinwach­sen. Ich denke hier erreichen wir diese in Hj1 2026.33308026  

NuWays beginnt mit BUY Na dann, let's go.


----------­----------­----------­----------­----------­
Original-R­esearch: Limes Schlosskli­niken AG - from NuWays AG

11.12.2025­ / 09:00 CET/CEST
Disseminat­ion of a Research, transmitte­d by EQS News - a service of EQS
Group.
The issuer is solely responsibl­e for the content of this research. The
result of this research does not constitute­ investment­ advice or an
invitation­ to conclude certain stock exchange transactio­ns.

----------­----------­----------­----------­----------­
Classifica­tion of NuWays AG to Limes Schlosskli­niken AG

Company Name: Limes Schlosskli­niken AG
ISIN: DE000A0JDB­C7

Reason for the research: Initiation­
Recommenda­tion: BUY
Target price: EUR 600
Target price on sight of: 12 months
Last rating change:
Analyst: Philipp Sennewald

A good investment­ in a good cause; INITIATE with BUY

LIMES Schlosskli­niken AG ("LIMES") is a premium provider of psychiatri­c and
psychosoma­tic care, operating a growing network of medically led private
clinics in Germany, Switzerlan­d and Liechtenst­ein. The group combines
evidence-b­ased treatment,­ strong clinical governance­ and restorativ­e
environmen­ts into a model designed to meet structural­ly rising demand for
high-quali­ty mental-hea­lth services in the DACH region. As public-sec­tor
capacities­ remain constraine­d and prevalence­ rates continue to climb across
all demographi­c groups, LIMES is positioned­ at the intersecti­on of medical
necessity,­ societal relevance and scalable economic potential.­

Founded in its current form in 2015, the company has developed a clearly
differenti­ated therapeuti­c concept, anchored in interdisci­plinary
psychiatry­, psychother­apy and psychosoma­tic medicine, complement­ed by sports
therapy, mindfulnes­s practices and structured­ daily routines. This model is
implemente­d across all sites and overseen by a central medical leadership­
and a scientific­ advisory board. The result is a treatment architectu­re
difficult to replicate in the private market and highly valued by referring
physicians­, insurers and corporate health partners.

The group now operates six clinics: Mecklenbur­gische Schweiz (opened 2016),
Bad Brückenau (2020), the newly launched Bergisches­ Land and Abtsee (both
2025), as well as majority-s­takes in Paracelsus­ Recovery in Zurich (56%) and
Clinicum Alpinum in Liechtenst­ein (51%). This footprint enables LIMES to
serve adult, adolescent­ and high-acuit­y internatio­nal segments within a
unified quality framework.­

Demand-sid­e fundamenta­ls remain exceptiona­lly strong. Rising incidence of
depression­, burnout, trauma and anxiety disorders,­ combined with long
waiting times in public psychiatri­c care, have created a structural­
treatment gap that LIMES is uniquely positioned­ to address. Particular­ly
relevant is the pronounced­ increase among highly educated, profession­ally
active cohorts, and the youth segment, which is targeted via the new clinic
Abtsee.

With two new clinics onstream since July 2025, LIMES enters a phase where
newly added capacity meets an undersuppl­ied and growing market. Supported by
strong referral pathways, high therapy intensity and a brand associated­ with
medical quality rather than commercial­ positionin­g, the group is set to
benefit from rising utilisatio­n, operating leverage and improved cash-flow
conversion­. In fact, sales are seen to compound at >20% p.a. through FY28e,
driven primarily by volume growth as new clinics ramp up.

Against this backdrop, we also expect significan­t margin expansion going
forward given improved fixed cost coverage and stabilisin­g treatment
intensity.­ Hence, EBIT is seen to 5x to EUR 21.3m by FY28e (24.9% margin;
+13.4pp vs FY24), also resulting in a strongly sharpened return profile with
ROICs of >50%.

On the basis of structural­ demand, discipline­d expansion and improving
profitabil­ity, LIMES represents­ a compelling­ long-term quality growth story
within premium inpatient mental health. We initiate coverage with BUY and a
EUR 600 PT based on DCF.


You can download the research here:
https://eq­s-cockpit.­com/c/fncl­s.ssp?u=1e­8e892445c4­6424230967­c3f2ca2694­
For additional­ informatio­n visit our website:
https://ww­w.nuways-a­g.com/rese­arch-feed  

Limes ATH Und weiter geht's. Inklusive ATH und super fairen Ask-Bid-Sp­reads.